Publisher
Springer Science and Business Media LLC
Subject
Urology,Gastroenterology,Radiology, Nuclear Medicine and imaging,Radiological and Ultrasound Technology
Reference14 articles.
1. Yamashita T, Kudo M, Ikeda K et al (2020) REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol 55:113–122
2. Fleeman N, Houten R, Chaplin M et al (2019) A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer 19:1209
3. Hiraoka A, Kumada T, Kariyama K et al (2019) Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med 8:137–146
4. Food and Drug Administration (2018). Lenvatinib (Lenvima). Food and Drug Administration, Maryland, The United States. Available via https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206947s007lbl.pdf. Accessed 2 Oct, 2020.
5. European Medicines Agency (2018). Lenvima-H-C-3727-II-0011-G : EPAR Assessment report. European Medicines Agency, Amsterdam, The Netherlands. Available via https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima. Accessed 2 Oct, 2020.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Lenvatinib;Reactions Weekly;2021-07